

Doxorubicin

NOT RECOMMENDED AS AN
ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

| | | | |
|--------------------------|---|----------------------------------|------------------------------------|
| | | EMLc | ATC codes: L01DB01 |
| Indication | Unspecified malignant neoplasms of ill-defined or unspecified sites | ICD11 code: 2D9Z | |
| INN | Doxorubicin | | |
| Medicine type | Chemical agent | | |
| List type | Complementary (EML) (EMLc) | | |
| Formulations | Parenteral > General injections > IV: 10 mg in vial (hydrochloride) ; 50 mg in vial (hydrochloride) | | |
| EML status history | First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1982 (TRS 685) Changed in 2002 (TRS 914) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents . ↗ | | |
| Tags | Cancer | | |
| Wikipedia | Doxorubicin ↗ | | |
| DrugBank | Doxorubicin ↗ | | |

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of doxorubicin was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for doxorubicin for more information.

